Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?

Abstract

Introduction: Globally, there is a considerable burden of HCV and HIV infections among people who inject drugs (PWID) and transmission of both infections continues. Needle and syringe programme (NSP) and opioid substitution therapy (OST) coverage remains low, despite evidence demonstrating their prevention benefit. Direct-acting antiviral therapies (DAA) with HCV cure >95% among PWID provide an opportunity to reverse rising trends in HCV-related morbidity and mortality and reduce incidence. However, HCV testing, linkage to care, and treatment remain low due to health system, provider, societal, and patient barriers. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <5% to 90% and number of eligible persons receiving HCV treatment from <1% to 80%. This commentary discusses why PWID should be considered as a priority population in these efforts, reasons why this goal could be attainable among PWID, challenges that need to be overcome, and key recommendations for action.

Discussion: Challenges to HCV elimination as a global health concern among PWID include poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low HCV testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. Key recommendations for action include reforming drug policies (decriminalization of drug use and/or possession, or providing alternatives to imprisonment for PWID; decriminalization of the use and provision of sterile needles-syringes; and legalization of OST for people who are opioid dependent), scaling up and improving funding for harm reduction services, making health services accessible for PWID, supporting community empowerment and community-based programmes, improving access to affordable diagnostics and medicines, and eliminating stigma, discrimination, and violence against PWID.

Conclusions: The ambitious targets for HCV elimination set by WHO are achievable in many countries, but will require researchers, healthcare providers, policy makers, affected communities, advocates, the pharmaceutical and diagnostics industries, and governments around the world to work together to make this happen.

References Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049): 1081–88. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791): 571–83. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 ckllaboration. Clin Infect Dis. 2017;64(7): 860–69. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7): e103345. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger Weinberger. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10): 1099–109. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(Suppl 2): S32–8. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7): 797–808. Larney S, Grebely J, Hickman M, De Angelis D, Dore GJ, Degenhardt L. Defining populations and injecting parameters among people who inject drugs: implications for the assessment of hepatitis C treatment programs. Int J Drug Policy. 2015;26(10): 950–57. Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 2. Journal of Viral Hepatitis. 2015;22(Suppl 1): 6–25. Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 3. Journal of Viral Hepatitis. 2015;22(Suppl 4): 4–20. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21(Suppl 1): 5–33. Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croat Med J. 2016;57(5): 442–56. Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014;34(8): 1198–206. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. J Viral Hepat. 2014;21(3): 198–207. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis. 2015;60(12): 1829–36. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9): 637–48. WHO. Global health sector strategy on viral hepatitis 2016-2021. 2017. Available from: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1 The Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastro Hepatol. 2017;2(3): 161–66. WHO. Global hepatitis report 2017. Geneva: World Health Organization; 2017. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9): 553–62. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009;102(1–3): 158–61. Alavi M, Law MG, Grebely J, Thein HH, Walter S, Amin J, et al. Lower life expectancy among people with an HCV notification: a population-based linkage study. J Viral Hepat. 2014;21(6): e10–8. Deans GD, Raffa JD, Lai C, Fischer B, Krajden M, Amin J, et al. Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. CMAJ Open. 2013;1(2): E68–76. Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18(1): 32–41. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15): 1979–91. Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158(9): 658–66. Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehpa SH. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study. Clin Infect Dis. 2017;65: 235–43. Mehta SH, McFall AM, Srikrishnan AK, Kumar MS, Nandagopal P, Cepeda J, et al. Morbidity and mortality among community-based people who inject drugs with a high hepatitis C and human immunodeficiency virus burden in Chennai, India. Open Forum Infect Dis. 2016;3(3): ofw121. Hayashi K, Milloy MJ, Wood E, Dong H, Montaner JS, Kerr T. Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study. J Int AIDS Soc. 2014;17: 19296. Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12): 1385–98. Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958): 1953–97. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1): 49–57. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65(1): 17–25. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6): 497–520. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4): 331–39. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312(18): 1927–28. Afdhal NH, Serfaty L. Effect of registries and cohort studies on HCV treatment. Gastroenterology. 2016;151(3): 387–90. Grebely J, Puoti M, Wedemeyer H, Cooper CS, Sulkowski MS, Foster GF, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepati ti s C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol. 2017;66: S514. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clini Infect Dis. 2016 Dec 1;63(11): 1479–81. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clini Infect Dis. 2016 Dec 1;63(11): 1405–11. Grebely J, Jacobson IM, Kayali Z, Verna EC, Shiffman ML, Hyland RH, et al. SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. J Hepatol. 2017;66: S513. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a randomized controlled trial (C-EDGE CO-STAR). Ann Intern Med. 2016 Nov 1;165(9): 625–34. DOI:10.7326/M16-0816. Christensen S, Schober A, Mauss S, Busch HW, Günther R, Teuber G, et al. DAA-treatment of HCV-infected patients on Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the German Hepatitis C-Registry (DHC-R). Hepatology. 2016;64(S1):982A–3A. Schutz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility-a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111(6): 903–05. Scherz N, Brunner N, Bruggmann P. Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data. J Hepatol. 2017;66: S726. Dillon J, Mauss S, Nalpas C, Bicer C, Schlag M, Lonjon-Domanec I, et al. Efficacyand safety of Simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy. J Hepatol. 2017;66: S520. Boyle A, Marra F, Fox R, Morris J, Fleming C, Reilly E, et al. Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone. J Hepatol. 2017;66: S282. Norton BL, Fleming J, Steinman M, Yu K, Deluca J, Co C, et al., editors. High HCV cure rates for drug users treated with DAAs at an urban primary care clinic. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22-24; Boston (MA). Conway B, Raycraft T, Bhutani Y, Kiani G, Shahi R, Singh A, et al. Efficacy of all-oral HCV therapy in people who inject drugs. Hepatology. 2016;64(S1):990A. Morris L, Smirnov A, Kvassay A, Leslie E, Kavanagh R, Alexander N, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland injectors’ health network. Int J Drug Policy. 2017 Jun 27. pii: S0955-3959(17)30160-3. DOI:10.1016/j.drugpo.2017.05.056. Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence amongst people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017 Jun 12. pii: S0955-3959(17)30129-9. DOI: 10.1016/j.drugpo.2017.05.025. Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017 Jun 4. pii: S0955-3959(17)30136-6. DOI:10.1016/j.drugpo.2017.05.032. Sulkowski M, Ward K, Falade-Nwulia O, Moon J, Sutcliffe C, Brinkley S, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS study. J Hepatol. 2017;66: S719. Litwin AH, Agyemang L, Akiyama M, Norton BL, Ning Y, Heo M, et al. The PREVAIL study: intensive models of HCV care for people who inject drugs. J Hepatol. 2017;66: S72. Bouscaillou J, Kikvidze T, Butsashvili M, Labartkava K, Inaridze I, Etienne A, et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. J Hepatol. 2017;66: S409. Boglione L, Mornese Pinna S, De Nicolo A, Cusato J, Cariti G, Di Perri G, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat. 2017. Grebely J, Dalgard O, Conway B, Cunningham E, Bruggmann P, Hajarizadeh B, et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study. J Hepatol. 2017;66: S513. Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol. 2015;12(4): 218–30. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clini Infect Dis. 2013;57(Suppl 2): S80–9. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clini Infect Dis. 2016;62(6): 683–94. Midgard H, Bjoro B, Maeland A, Konopski Z, Kileng H, Damas JK, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64(5): 1020–26. Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug Alcohol Depend. 2016;165: 53–60. Pineda JA, Nunez-Torres R, Tellez F, Mancebo M, Garcia F, Merchante N, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect. 2015;71(5): 571–77. Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV. Clini Infect Dis. 2017;64: 1154–62. Dore GJ, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: co-STAR three year follow-up study. Hepatology. 2016;64(S1):431A. Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. 2017 Aug;66(8): 1507–15. DOI:10.1136/gutjnl-2016-311504. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5): 1598–609. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clini Infect Dis. 2013;57(Suppl 2): S39–45. European Union HCVC. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5): 325–36. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6): 1137–44. de Vos AS, Prins M, Kretzschmar ME. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction. 2015;110: 975–83. Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60(6): 1861–70. Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, et al. Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs? PLoS One. 2015;10(12): e0143836. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 Jul 8;(3): CD002209. DOI: 10.1002/14651858. CD002209.pub29. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;(2): CD002207. DOI: 10.1002/14651858. CD002207.pub4. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10): 1028–38. Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12): 2053–59. Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the networks II study. Int J Drug Policy. 2014;25(1): 179–82. White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust. 2014;201(6): 326–29. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12): 1974–81. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1): 34–52. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737): 285–301. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1): 74–83. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11): 1978–88. Van Den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22(3): 183–93. Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev. 2016;2016(1). pii: CD012021. Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1): 235–48. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt Hurt. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1): S5–11. HRI. Global state of harm reduction 2016. London: Harm Reduction International; 2016. WHO, UNODC, UNAIDS. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users—2012 revision. Geneva; 2013. DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV. 2017 May 12. pii: S2352–3018(17)30073–5. DOI: 10.1016/S2352-3018(17)30073-5. Bruggmann P, Prevention GJ. Treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(Suppl 1): S22–6. Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna declaration: a call for evidence-based drug policies. Lancet. 2010;376(9738): 310–12. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738): 355–66. Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026): 1427–80. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4): 1215–24. Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study. J Viral Hepat. 2017 Mar 3. DOI:10.1111/jvh.12701. Champion JK, Taylor A, Hutchinson S, Cameron S, McMenamin J, Mitchell A, et al. Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol. 2004;159(5): 514–19. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049): 1089–102. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651): 1733–45. Topp L, Iversen J, Conroy A, Salmon AM, Maher L, Collaboration of Australian N. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Aust N Z J Public Health. 2008;32(1): 34–7. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1): 32–51. McCutcheon JM, Morrison MA. Injecting on the Island: a qualitative exploration of the service needs of persons who inject drugs in Prince Edward Island, Canada. Harm Reduct J. 2014;11: 10. McKnight C, Shumway M, Masson CL, Pouget ER, Jordan AE, Des Jarlais DC, et al. Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J Ethn Subst Abuse. 2017: 1–16. Heath AJ, Kerr T, Ti L, Kaplan K, Suwannawong P, Wood E, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. J Public Health. 2016;38(3): e301–e8. Calabrese SK, Burke SE, Dovidio JF, Levina OS, Uuskula A, Niccolai LM, et al. Internalized HIV and drug stigmas: interacting forces threatening health status and health service utilization among people with HIV who inject drugs in St. Petersburg, Russia. AIDS Behav. 2016;20(1): 85–97. Terlikbayeva A, Zhussupov B, Primbetova S, Gilbert L, Atabekov N, Giyasova G, et al. Access to HIV counseling and testing among people who inject drugs in Central Asia: strategies for improving access and linkages to treatment and care. Drug Alcohol Depend. 2013;132(Suppl 1): S61–4. Guise A, Rhodes T, Ndimbii J, Ayon S, Nnaji O. Access to HIV treatment and care for people who inject drugs in Kenya: a short report. AIDS Care. 2016;28(12): 1595–99. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10: 7. Wilson H, Brener L, Mao L, Treloar C. Perceived discrimination and injecting risk among people who inject drugs attending needle and syringe programmes in Sydney, Australia. Drug Alcohol Depend. 2014;144: 274–78. United Nations Office on Drugs and Crime INoPWUD, Joint United Nations Programme on HIV/AIDS, United Nations Development Programme, United Nations Population Fund, World Health Organization, United States Agency for International Development. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. 2017. Available from: http://www.unodc.org/documents/hiv-aids/publications/Implementing_Comprehensive_HIV_and_HCV_Programmes_with_People_Who_Inject_Drugs_PRACTICAL_GUIDANCE_FOR_COLLABORATIVE_INTERVENTIONS.pdf Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clini Infect Dis. 2013;57(Suppl 2): S56–61. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. Int J Drug Policy. Forthcoming 2017. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1): 109–20. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open. 2016;4(4): E605–E14. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine. 2015;163(3): 215–23. AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C: AASLD/IDSA. 2017 Available from: https://www.hcvguidelines.org/ EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1): 153–94. WHO. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Geneva: WHO; 2016. Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments—is this fair, given the available data? J Hepatol. 2015;63(4): 779–82. Marshall AD, Nielsen S, Cunningham EB, Aghemo A, Alho H, Backmund M, et al. Restrictions for reimbursement of interferon-free direct acting antiviral therapies for HCV infection in Europe. J Hepatol. 2017;66(1): S95–S6. Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. J Hepatol. 2017;66(1): S291–S2. WHO. Global policy report on the prevention and control of viral hepatitis. 2013. Available from: http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf WHO. Manual for the development and assessment of national viral hepatitis plans. 2015. Available from: http://apps.who.int/iris/bitstream/10665/183726/1/9789241509350_eng.pdf?ua=1